

10 July 2024

Treatment of Melanoma

I have a freedom of information request regarding the treatment of melanoma

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- **Cobimetinib** <5
- **Dabrafenib** <5
- **Dabrafenib + Trametinib** 6
- **Dacarbazine** <5
- **Denosumab** <5
- **Encorafenib + Binimetinib** 14
- **Ipilimumab monotherapy** <5
- **Ipilimumab + Nivolumab** 9
- **Nivolumab monotherapy** 9
- **Nivolumab + Relatlimab** <5
- **Pembrolizumab** 50
- **Trametinib** <5
- **Vemurafenib** <5
- **Vemurafenib + Cobimetinib** <5
- **Other active systemic anti-cancer therapy** Tebentafusp MAP <5
- **Palliative care only** Not available on RISOH

Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:

- **Ipilimumab monotherapy**
- **Ipilimumab + Nivolumab**
- **Nivolumab monotherapy**
- **Nivolumab + Relatlimab**
- **Pembrolizumab**
- **Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)**
- **Other active systemic anti-cancer therapy**

10 July 2024

- **Palliative care only**

Not available on RISOH

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

- **Ipilimumab (monotherapy) <5**
- **Nivolumab (monotherapy) <5**
- **Nivolumab AND Ipilimumab (combination) 7**
- **Nivolumab AND Relatlimab <5**
- **Pembrolizumab 16**
- **Any Targeted Therapy (Dabrafenib <5 /Dabrafenib AND Trametinib <5 /Encorafenib AND Binimetinib 5 /Trametinib <5 /Vemurafenib <5 /Vemurafenib <5 AND Cobimetinib <5)**
- **Other active systemic anti-cancer therapy**

* Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.